ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Germline and somatic DNA repair gene alterations in prostate cancer

Marc A. Dall’Era MD; John D. McPherson PhD; Allen C. Gao MD, PhD; Ralph W. DeVere White MD; Jeffrey P. Gregg MD; Primo N. Lara Jr MDUniversity of California at Davis
Cancer2020DOI: 10.1002/cncr.32908
19被引10阅读
引用收藏
分享

摘要

BackgroundEmerging evidence has suggested that DNA repair gene alterations may be important in prostate cancer pathogenesis. In the current study, the authors sought to characterize alterations in DNA repair pathway genes in both primary and metastatic prostate tumors with attention to tissue distribution as well as specific genomic alterations.MethodsThe authors studied the distribution and type of alterations in 24 genes that are considered important for DNA repair in 944 prostate cancers harvested from localized and metastatic tumors. Tumor DNA underwent hybrid capture for all coding exons of 287 or 395 cancer‐related genes plus select introns from 19 or 31 genes frequently rearranged in cancer. Captured libraries were sequenced to a median exon coverage depth of >×500. Specific genomic alterations were characterized and the frequencies of mutations by tissue site (prostate vs metastases) were compared using logistic regression.ResultsA total of 152 patients from the cohort of 944 men (16%) harbored a germline or somatic mutation in ≥1 DNA repair genes. The most frequently mutated genes were BRCA2 (11.4%) and ATM (5.8%), followed by MSH6 (2.5%) and MSH2 (2.1%). Mutations were identified in approximately 20.1% of primary prostate tumors compared with 18.8% of bone metastases. When stratified by tissue site, the highest rates of DNA repair mutations were found in solid organ metastases, including brain and visceral metastases, compared with prostate.ConclusionsDNA repair gene mutations are more common in metastatic than localized prostate tumors. Visceral and other solid organ metastases appear enriched for these mutations compared with localized tumors or bone and lymph node metastases.

学科与关键词

关键词
DNA repairGenomicsPoly(adenosine diphosphate ribose) polymerase (PARP) inhibitorProstate cancer
相关
加载中…
  • Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
    Antonarakis Emmanuel S*; Luber Brandon; Wang Hao; Isaacs William B; Luo Jun*; Antonarakis Emmanuel S; Lu Changxue; Liang Chao; Chen Yan; Silberstein John L; Piana Danilo; Isaacs William B; Luo Jun; Lai Zhao; Chen Yidong; Chen Yidong; Antonarakis ES*; Luo J*; Antonarakis ES; Luo JEuropean Urology, 2018, 74(2): 218-225.被引 2
  • Prostate Cancer with Germline DNA Damage Repair Gene Alterations: A Clinical and Pathologic Assessment
    Gopalan, Anuradha; Fine, Samson; Chen, Ying-Bei; Al-Ahmadie, Hikmat; Sarungbam, Judy; Abida, Wassim; Scher, Howard; Tickoo, Satish; Reuter, Victor109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Los Angeles, CA, 2020-02-29 To 2020-03-05.
  • Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients
    Junlong Wu; Yu Wei; Jian Pan; Shengming Jin; Weijie Gu; Hualei Gan; Yao Zhu; Ding Wei YeInternational Journal of Cancer, 2021, 148(3).
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer
发表日期
2020
卷期
第 126 卷, 第 13 期
页码
2980-2985
DOI
10.1002/cncr.32908
成果收录
CHINAJOURNAL

作者

  • M

    Marc A. Dall’Era MD (第一作者)

  • J

    John D. McPherson PhD

查看全部 6 位作者收起作者
  • A

    Allen C. Gao MD, PhD

  • R

    Ralph W. DeVere White MD

  • J

    Jeffrey P. Gregg MD

  • P

    Primo N. Lara Jr MD

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417